Skip to main content

sciencce

COVID trial using antidepressant cut short due to apparent effectiveness

posted onOctober 29, 2021
by l33tdawg
Credit: Arstechnica

Despite the wide availability of vaccines, the most recent surge in COVID-19 cases left several US states struggling to provide adequate health care to their citizens. The situation reinforces the potential value of drugs like molnupiravir, which reduce the need for hospitalization among those with COVID-19. But monupiravir will be expensive and will likely be difficult to supply globally for some time. So ongoing trials that test existing drugs for effectiveness against COVID-19 can still provide significant value.